FDA Adverse Event Death Summary report: N

ONYX

MDR report key: 13615106 · Received February 27, 2022

Report

Report Number
2029214-2022-00319
Event Type
Death
Date Received
February 27, 2022
Date of Event
December 24, 2021
Report Date
February 27, 2022
Manufacturer
MICRO THERAPEUTICS, INC. DBA EV3
Product Code
MFE
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

WANG, M., LIN, F., QIU, H., CAO, Y., WANG, S., ZHAO, J. (2021). COMPARISON OF ENDOVASCULAR EMBOLIZATION PLUS SIMULTANEOUS MICROSURGICAL RESECTION VS. PRIMARY MICROSURGICAL RESECTION FOR HIGH-GRADE BRAIN ARTERIOVENOUS MALFORMATIONS. FRONTIERS IN NEUROLOGY, 12. HTTP S://DOI.ORG/10.3389/FNEUR.2021.756307. AGE OR DATE OF BIRTH. THIS VALUE IS THE AVERAGE AGE OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. SEX. THIS VALUE REFLECTS THE GENDER OF THE MAJORITY OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. DATE OF EVENT. PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF PUBLICATION OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE EVENTS REPORTED WITH PREVIOUSLY REPORTED EVENTS. CORRESPONDENCE HAS BEEN SENT TO THE AUTHOR OF THE ARTICLE INQUIRING ABOUT INDIVIDUAL PATIENT INFORMATION AND ADDITIONAL INFORMATION REGARDING THE REPORTED EVENTS. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Additional Manufacturer Narrative · 0

WANG, M., LIN, F., QIU, H., CAO, Y., WANG, S., ZHAO, J. (2021). COMPARISON OF ENDOVASCULAR EMBOLIZATION PLUS SIMULTANEOUS MICROSURGICAL RESECTION VS. PRIMARY MICROSURGICAL RESECTION FOR HIGH-GRADE BRAIN ARTERIOVENOUS MALFORMATIONS. FRONTIERS IN NEUROLOGY, 12. HTTP S://DOI.ORG/10.3389/FNEUR.2021.756307. AGE OR DATE OF BIRTH. THIS VALUE IS THE AVERAGE AGE OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. SEX. THIS VALUE REFLECTS THE GENDER OF THE MAJORITY OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. DATE OF EVENT. PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF PUBLICATION OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE EVENTS REPORTED WITH PREVIOUSLY REPORTED EVENTS. CORRESPONDENCE HAS BEEN SENT TO THE AUTHOR OF THE ARTICLE INQUIRING ABOUT INDIVIDUAL PATIENT INFORMATION AND ADDITIONAL INFORMATION REGARDING THE REPORTED EVENTS. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

WANG, M., LIN, F., QIU, H., CAO, Y., WANG, S., ZHAO, J. (2021). COMPARISON OF ENDOVASCULAR EMBOLIZATION PLUS SIMULTANEOUS MICROSURGICAL RESECTION VS. PRIMARY MICROSURGICAL RESECTION FOR HIGH-GRADE BRAIN ARTERIOVENOUS MALFORMATIONS. FRONTIERS IN NEUROLOGY, 12. HTTP S://DOI.ORG/10.3389/FNEUR.2021.756307. SUMMARY: IT REMAINS A CHALLENGE IN SURGICAL TREATMENTS OF BRAIN ARTERIOVENOUS MALFORMATIONS (AVMS) IN SPETZLER-MARTIN GRADE (SMG) IV AND V TO ACHIEVE BOTH OPTIMAL NEUROLOGICAL OUTCOMES AND COMPLETE OBLITERATION. THE AUTHORS REPORTED A SERIES OF PATIENTS WITH AVMS IN SMG IV AND V WHO UNDERWENT A SURGICAL PARADIGM OF ENDOVASCULAR EMBOLIZATION AND SIMULTANEOUS MICROSURGICAL RESECTION BASED ON THE ONE-STAGED HYBRID OPERATION. IDENTIFIED EVENTS: 1. TWO PATIENTS DIED, ONE WAS TWO MONTHS AFTER THE OPERATION, AND THE OTHER DEATH WAS 24 MONTHS IN A COMA.

Description of Event or Problem · 0

WANG, M., LIN, F., QIU, H., CAO, Y., WANG, S., ZHAO, J. (2021). COMPARISON OF ENDOVASCULAR EMBOLIZATION PLUS SIMULTANEOUS MICROSURGICAL RESECTION VS. PRIMARY MICROSURGICAL RESECTION FOR HIGH-GRADE BRAIN ARTERIOVENOUS MALFORMATIONS. FRONTIERS IN NEUROLOGY, 12. HTTP S://DOI.ORG/10.3389/FNEUR.2021.756307. SUMMARY: IT REMAINS A CHALLENGE IN SURGICAL TREATMENTS OF BRAIN ARTERIOVENOUS MALFORMATIONS (AVMS) IN SPETZLER-MARTIN GRADE (SMG) IV AND V TO ACHIEVE BOTH OPTIMAL NEUROLOGICAL OUTCOMES AND COMPLETE OBLITERATION. THE AUTHORS REPORTED A SERIES OF PATIENTS WITH AVMS IN SMG IV AND V WHO UNDERWENT A SURGICAL PARADIGM OF ENDOVASCULAR EMBOLIZATION AND SIMULTANEOUS MICROSURGICAL RESECTION BASED ON THE ONE-STAGED HYBRID OPERATION. IDENTIFIED EVENTS: 1. TWO PATIENTS DIED, ONE WAS TWO MONTHS AFTER THE OPERATION, AND THE OTHER DEATH WAS 24 MONTHS IN A COMA.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1303309 ONYX AGENT, INJECTABLE, EMBOLIC MFE MICRO THERAPEUTICS, INC. DBA EV3 UNK-NV-ONYX UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 27 YR Male Required Intervention| D| H